-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

616.O2.6 616. Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies: New Treatment Approaches for AML

Symposia: Acute Myeloid Leukemias: Investigational Drug and Cellular Therapies Program: Oral and Poster Abstracts
Type: Oral
Hematology Disease Topics & Pathways:
Acute Myeloid Malignancies, Research, Clinical trials, AML, Adult, Clinical Research, Diseases, Adverse Events, Myeloid Malignancies, Study Population, Human, Measurable Residual Disease
Monday, December 9, 2024: 10:30 AM-12:00 PM
Grand Hall B (Manchester Grand Hyatt San Diego)
Moderators:
Mathew G. Angelos, MD, PhD, and Naval Daver, MD, MD Anderson Cancer Center
Disclosures:
No relevant conflicts of interest to declare.
This session is dedicated to new therapeutics in AML (phase I/II)
10:30 AM

Daniel J. DeAngelo, MD, PhD1, Andre C. Schuh, MD, FRCPC2, Brian A. Jonas, MD, PhD3, Pamela S. Becker, MD, PhD4, Anjali S. Advani, MD5, Geoffrey L. Uy, MD6, Janusz Krawczyk, MD7, Harry P. Erba, MD, PhD8, Gabriel N Mannis, MD9, Chun Yew Fong, MBBS, FRACP, FRCPA, PhD10*, Florian Kuchenbauer, MD, PhD, FRCPC11, Mary-Elizabeth M. Percival, MD12, Jane L. Liesveld, MD13, William Blum, MD14, Brenda W Cooper, MD15, Alice Mims, MD16, Francesco Lanza, MD17,18*, Jeroen J.W.M. Janssen19, Juan Miguel Bergua Burgues, MD20*, Tibor Kovacsovics, MD21*, Norbert Vey, MD22, Martina V. Hemmer, MA23*, Gaetano Bonifacio, MD23*, Edwin Rock, MD, PhD23 and Pau Montesinos, PhD, MD24*

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Medical Oncology and Hematology, University Health Network- University of toronto, Toronto, ON, Canada
3UC Davis Comprehensive Cancer Center, Davis, CA
4Hematology/HCT, City of Hope, Duarte, CA
5Department of Hematology and Medical Oncology, Cleveland Clinic Taussig Cancer Institute, Cleveland, OH
6Washington University School of Medicine, Saint Louis
7Department of Haematology, University Hospital Galway, H91 Galway, Ireland; National University of Ireland, H91, Galway, Ireland
8Duke University Cancer Institute, Durham, NC
9Stanford, Stanford Cancer Center, Menlo Park, CA
10Department of Hematology, Austin Health, Heidelberg, VIC, Australia
11Leukemia/Bone Marrow Transplant Program of British Columbia, British Columbia Cancer Agency, Vancouver, Canada
12Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
13Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
14Emory University, Winship Cancer Institute, Atlanta, GA
15Department of Hematology and Stem Cell Transplant, University Hospitals Seidman Cancer Center, Cleveland, OH
16The Ohio State University Comprehensive Cancer Center, Columbus, OH
17Division of Hematology, Onco-hematologic Department, AUSL della Romagna, Ravenna, Italy
18Hematology Unit and Metropolitan Romagna Transplant Network, University of Bologna, Ravenna, Italy
19Department of Hematology, Amsterdam University Medical Centers, VUmc, Amsterdam, Netherlands
20Hospital San Pedro de Alcántara, Caceres, Spain
21City of Hope Phoenix, Goodyear, AZ
22Paoli-Calmette Cancer Institute, Marseille, France
23GlycoMimetics, Inc., Rockville, MD
24Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain

10:45 AM

Ian M. Bouligny, MD1, Hagop M. Kantarjian, MD1, Musa Yilmaz, MD1*, Naval Daver, MD2, Gautam Borthakur, MD3, Courtney D. DiNardo, MD, MSc1, Guillermo Montalban-Bravo, MD1, Nicholas J. Short, MD1, Yesid Alvarado Valero, MD1, Elias Jabbour, MD1, Nitin Jain, MD1, Naveen Pemmaraju, MD1, Danielle Hammond, MD1, Kelly S. Chien, MD4, Koichi Takahashi, MD, PhD5, Ghayas C. Issa, MD1, Hussein A. Abbas, MD, PhD1, Guillermo Garcia-Manero, MD1, Farhad Ravandi, MBBS6 and Tapan M. Kadia, MD1

1Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
2MD Anderson Cancer Center, Houston, TX
3Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, MD Anderson, Houston, TX
5Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
6Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX

11:00 AM

Sankalp Arora, MBBS1, Jayastu Senapati, MD, DM, MBBS2, Sanam Loghavi, MD3, Patrick K. Reville, MD, MPH2, Bofei Wang, PhD4, Tapan M. Kadia, MD2, Courtney D. DiNardo, MD, MSc5, Naveen Pemmaraju, MD2, Musa Yilmaz, MD2*, Joseph E. Jabbour6*, Nicholas J. Short, MD2, Guillermo Montalban-Bravo, MD2, Abhishek Maiti, MBBS2, Guilin Tang, MD, PhD3*, Koji Sasaki, MD2, Gautam Borthakur, MD7, Joie Alvarez, BSN8*, Sherry Pierce, BSN, BA2*, Graciela M. Nogueras González8*, Jing Ning, PhD9*, Ghayas C. Issa, MD2, Michael Andreeff, MD, PhD7, Farhad Ravandi, MBBS10, Guillermo Garcia-Manero, MD2, Hussein A. Abbas, MD, PhD2 and Naval Daver, MD11

1Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
2Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
3Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
4Department of Leukemia, Division of Cancer Medicine, The University of Texas At MD Anderson Cancer Cent, Houston, TX
5Department of Leukemia, UT MD Anderson Cancer Center, Houston, TX
6Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX
7Section of Molecular Hematology and Therapy, Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX
8The University of Texas MD Anderson Cancer Center, Houston, TX
9The University of Texas M.D. Anderson Cancer Center, Houston, TX
10Department of Leukemia, University of Texas- MD Anderson Cancer Center, Houston, TX
11MD Anderson Cancer Center, Houston, TX

11:15 AM

Jessica M. Stempel, MD1, Geoffrey L. Uy, MD2, Shira N. Dinner, MD3, Ivana Gojo, MD4, Daniel R Reed, MD5,6, Rupali Roy, MD6*, Kenneth P Byrd, DO7, Swaroopa Yerrabothala, MD8, Catherine E. Lai, MD9,10, Kimberley Doucette, MD10, Anne Caldwell, RN1*, Ondrej Blaha, PhD1,11*, Nikolai A. Podoltsev, MD, PhD1, Lourdes M Mendez, MD, PhD1*, Jan Philipp Bewersdorf, MD1, Tariq Kewan, MD1, Ignacio Wistuba, MD12*, Gheath Alatrash, PhD, DO13, Cara L Haymaker, PhD14*, Howard Streicher, MD15*, Elad Sharon, MD, MPH16*, Richard F. Little, MD, MPH15, Steven D. Gore, MD15, Jerald P. Radich, MD17, Brent L. Wood, MD, PhD18, Amer M. Zeidan, MBBS, MHS1 and Rory M. Shallis, MD1

1Section of Hematology, Department of Internal Medicine, Yale School of Medicine, New Haven, CT
2Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
3Robert H. Lurie Comprehensive Cancer Center, Northwestern University, Chicago, IL
4Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University School of Medicine, Baltimore, MD
5Department of Medicine, Division of Hematology and Oncology, University of Virginia Medical Center Comprehensive Cancer Center, Charlottesville, VA
6Section on Hematology and Medical Oncology, Wake Forest University School of Medicine, Wake Forest Baptist Health Comprehensive Cancer Center, Winston-Salem, NC
7Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Leawood, KS
8Dartmouth Hitchcock Medical Center, Lebanon, NH
9Division of Hematology and Oncology, Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA
10Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC
11School of Public Health, Department of Biostatistics, Yale University, New Haven
12Department of Translational Molecular Pathology, University of Texas MD Anderson Cancer Center, Houston, TX
13Department of Hematopoietic Biology and Malignancy, University of Texas MD Anderson Cancer Center, Houston
14Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX
15Cancer Therapy Evaluation Program, National Cancer Institute, Bethesda, MD
16Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA
17Translational Sciences and Therapeutics Division, Fred Hutchinson Cancer Rsch. Ctr., Seattle, WA
18Department of Pathology and Laboratory Medicine, Children's Hospital Los Angeles, Los Angeles, CA

11:30 AM

Eric S. Winer, MD1, David Sallman, MD2, Adolfo De la Fuente Burguera, MD3*, Amit Verma, MBBS4*, Katharina Goetze, MD5*, Yasmin Abaza, MD6, James P. Dugan, MD7, Thomas Cluzeau, MD, PhD8*, Eduardo Rodriguez Arboli, MD MPhil9*, Alice Mims, MD10, Stefanie Groepper, MD11*, Itay Zilbershatz, MD12*, Jane L. Liesveld, MD13, Walter Fiedler, MD14, Stefano R Tarantolo, MD15, Lionel Ades, MD, PhD16, Nikolaos Papadantonakis, MD17*, Christoph Schliemann, MD18*, Gaurav S Choudhary, PhD19*, Maureen Lane, PhD19*, Wanying Zhao, PhD19*, Ashish Jain, MS19*, Cole Gallagher, BS19* and Guillermo Garcia-Manero, MD20

1Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA
2Department of Malignant Hematology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL
3MD Anderson Cancer Center, Madrid, ESP
4Albert Einstein College of Medicine, Bronx, NY
5Clinic and Polyclinic for Internal Medicine III, Klinikum rechts der Isar, Muenchen, DEU
6Northwestern University, Chicago, IL
7Malignant Hematology and Cellular Therapy Department, Novant Health Cancer Institute - Forsyth Medical Center, Winston, Salem, NC
8Centre Hospitalier Universitaire de Nice, Nice, France
9Department of Hematology, Hospital Universitario Virgen del Rocío, Instituto de Biomedicina de Sevilla (IBIS/CSIC), University of Seville, Sevilla, Spain
10Clara D. Bloomfield Center for Leukemia Outcomes Research, The Ohio State University Comprehensive Cancer Center, Columbus, OH
11Marien Hospital, University of Düsseldorf, Düsseldorf, Germany
12The Edith Wolfson Health Center, Holon, Israel
13Wilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY
14Department of Medicine II, University Hospital Eppendorf, Hamburg, Germany
15Nebraska Cancer Specialists, Omaha, NE
16Hopital Saint Louis, Paris, France
17Winship Cancer Institute of Emory University, Atlanta, GA
18Department of Medicine A, University Hospital Muenster, Muenster, Germany
19Curis Inc., Lexington, MA
20Department of Leukemia, The University of Texas MD Anderson Cancer Center, Houston, TX

11:45 AM

Pau Montesinos, PhD, MD1*, Montserrat Arnan, MD, PhD2*, Stephane De Botton3*, Maria Calbacho, MD4*, Rebeca Rodriguez Veiga, MD, PhD5*, Pierre Bories, MD6*, Belén Ansoleaga, MD, PhD7*, Thomas Hueso, MD, PhD8*, Naval Daver, MD9, Lydia Wunderle, MD10*, Andreas Harstrick, MD10*, Kerstin Pietzko10*, Pallavi Hajela10*, Alexandra Vasile, PhD11*, Tania Witte, PhD12*, Elmarie Saenger10* and Christian Récher, MD13*

1Hematology, Hospital Universitari I Politécnic La Fe and Programa Español de Tratamientos en Hematología (PETHEMA) Group, Valencia, Spain
2Hematology Department. Institut Català d’Oncologia, Hospital Duran i Reynals. Institut d’Investigació Biomèdica de Bellvitge (IDIBELL). Universitat de Barcelona, Hospitalet de Llobregat, Barcelona, Spain
3Department of Hematology, Institut Gustave Roussy, Villejuif Cedex, France
4Hematology Department, Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain
5Hospital Universitary i Politecnic La Fe, Valencia, ESP
6CHU de Toulouse-Institut Universitaire du Cancer Toulouse de Toulouse Oncopole, Toulouse, France
7Institut Català d’Oncologia-Hospital Duran i Reynals, Institut d’Investigacio Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
8Institut Gustave Roussy, Villejuif Cedex, France
9University of Texas MD Anderson Cancer Center, Houston, TX
10Affimed GmbH, Mannheim, Germany
11Affimed GmBH, mannheim, Germany
12Affimed GmbH, Manheim, Germany
13IUCT-Oncopole, Hematology Department, CHU Toulouse, Toulouse, France

*signifies non-member of ASH